35 results
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
19 Apr 24
Current report (foreign)
6:12am
dosing with ENTYVIO and refer to neurologist; if confirmed, discontinue ENTYVIO dosing permanently. Liver Injury: There have been reports … of significant liver injury. Live and Oral Vaccines: Prior to initiating treatment with ENTYVIO, all patients should be brought up to date with all
6-K
TAK
Takeda Pharmaceutical Co
28 Sep 23
Current report (foreign)
6:17am
, withhold dosing with ENTYVIO and refer to neurologist; if confirmed, discontinue ENTYVIO dosing permanently.
Liver Injury: There have been reports … evidence of significant liver injury.
Live and Oral Vaccines: Prior to initiating treatment with ENTYVIO, all patients should be brought up to date with all
6-K
TAK
Takeda Pharmaceutical Co
8 Dec 22
Current report (foreign)
6:46am
injection. It is important that precautions are in place to avoid injury from fainting. A protective immune response with Qdenga may not be elicited
6-K
EX-99.1
avh1om
23 Aug 22
Current report (foreign)
6:13am
S-8
EX-99.1
1m105mn
29 Jun 22
Registration of securities for employees
6:13am
6-K
EX-99.1
ioqmgjs q9ckvp8u
6 Apr 21
Current report (foreign)
6:29am
6-K
EX-99.1
woo seq4nuch
17 Dec 20
Current report (foreign)
6:01am
6-K
EX-99.1
d4o 5385kqb0
10 Jan 20
Better Health, Brighter Future 2019 SUSTAINABLE VALUE REPORT Takeda Pharmaceutical Company Limited
6:36am
6-K
EX-99.1
c1i3 4jset
21 Nov 19
Current report (foreign)
6:08am
6-K
EX-99.1
5z6we5m1npmo0vxb
14 Nov 19
Current report (foreign)
6:26am
424B3
4stjqei z519i6
14 Nov 19
Prospectus supplement
6:10am
F-4/A
vz7wbbwtv6r
12 Nov 19
Registration of securities (foreign) (amended)
9:50am
F-4
r4jmcy9ifvw6hp38
9 Aug 19
Registration of securities (foreign)
6:27am
20-F
s0m3kk7ltdjnkks
27 Jun 19
Annual report (foreign)
6:41am
20FR12B/A
EX-10.5
50hyiihgkl2l0
17 Dec 18
Initial registration of securities (foreign private issuers) (amended)
6:14am